It’s little surprise that Tim is ranked in the Legal 500 as a ‘next generation’ pharma and biotech lawyer. With a long-held interest in the field, allied to scientific training, he is a firm believer in the transformative power of life sciences and the remarkable impact they can have on people’s lives.
Today, his principal focus is on patents and related rights, providing strategic advice and litigation expertise in the English Courts to innovator biotech and pharma companies. In helping his clients enforce, defend and understand their IP rights and minimise their risks, Tim has advised on numerous blockbuster pharmaceutical and biotech treatments, including various monoclonal antibody therapies.
The approach he takes to this work is always collaborative - he often works as part of a multi-jurisdictional team and relishes the challenge of forming and deploying creative legal and commercial strategies.
Tim is equally active in supporting the next generation of leaders in life sciences and healthcare. He enjoys regular lecturing and teaching, and working with entrepreneurs, start-ups and spin-outs, helping them understand how to use IP to protect their innovations.
Highly regarded in the wider industry, Tim is a member of the European Patent Lawyers Association (EPLAW) and Co-chair of the Biotech litigation subcommittee of the American Intellectual Property Lawyers Association (AIPLA), and teaches on Oxford University's Postgraduate Intellectual Property Diploma.
IP basics: what to think about when entering the UK and EU markets (trade marks, copyright, designs)
The Russian government has responded to western sanctions with new legislation designed to undermine the intellectual property (IP) rights of...